Cronos Group

Historical price data

Cronos Group's mission is to build a leading, science-driven cannabinoid platform that delivers high-quality products to global consumer and medical markets. A key achievement was securing a C$2.4 billion strategic investment from Altria Group in 2019, providing a robust balance sheet to fund R&D and international expansion. The company's strategy is anchored in differentiating through its fermentation-based cannabinoid production technology, brand portfolio management, and navigating complex international regulatory pathways. Its operational focus spans cultivation, product development, and distribution in key legal markets.

Proprietary fermentation platform, developed in partnership with Ginkgo Bioworks, for the biosynthesis of cultured cannabinoids using engineered microorganisms, aiming for scalable, consistent, and cost-effective production.